Emn Trial Office S.r.l. Impresa Sociale
Emn Trial Office S.r.l. Impresa Sociale is recorded as a service provider in 9 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 9 of 9 trials · Latest update first
A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Multi-cohort Study Applying Innovative MRD Techniques for Transplant Eligible Participants with Previously Untreated Multiple Myeloma - TAURUS
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A PHASE 3 RANDOMIZED, OPEN-LABEL TRIAL OF SELINEXOR, POMALIDOMIDE, AND DEXAMETHASONE (SPd) VERSUS ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EloPd) IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A multicenter, open label, randomized phase II study comparing daratumumab combined with bortezomib-cyclophosphamide-dexamethasone (Dara-VCd) versus the association of bortezomib-thalidomide-dexamethasone (VTd) as pre transplant induction and post transplant consolidation, both followed by a maintenance phase with ixazomib alone or in combination with daratumumab, in newly diagnosed multiple myeloma (MM) young patients eligible for autologous stem cell transplantation
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase III study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone (Isa-KRd) versus Carfilzomib-Lenalidomide-Dexamethasone (KRd) in newly diagnosed multiple myeloma patients eligible for autologous stem cell transplantation (IsKia TRIAL)
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase II study of iberdomide (CC220) maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients
Sponsor European Myeloma Network B.V.
- Start (EU)
- Latest update
- Estimated end
- Not reported
CARFILZOMIB - LENALIDOMIDE - DEXAMETHASONE (KRd) versus LENALIDOMIDE - DEXAMETHASONE (Rd) IN NEWLY DIAGNOSED MYELOMA PATIENTS NOT ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A RANDOMIZED PHASE III TRIAL (EMN20)
Sponsor Fondazione European Myeloma Network Italy O.N.L.U.S.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Daratumumab, pomalidomide and dexamethasone for del(17p) positive relapsed and relapsed/refractory multiple myeloma patients [DEDALO]
Sponsor Fondazione European Myeloma Network Italy O.N.L.U.S.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Emn Trial Office S.r.l. Impresa Sociale?
The 2026-10-09 snapshot links Emn Trial Office S.r.l. Impresa Sociale to 9 distinct CTIS trials. Recorded services include Laboratory services, Correlative evaluation of the humoral and cellular immune response to SARS-CoV-2, Correlatives: immune cell phenotyping, gene expression and immune receptor sequencing (on BM and PB), CHIP and germline sequencing (on BM and PB), CTC enumeration, biopsy for imaging , MRD by NGF, FISH, Immunophenotype, MRD negativity con NGF, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Emn Trial Office S.r.l. Impresa Sociale?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Emn Trial Office S.r.l. Impresa Sociale conducted?
The linked trials record locations in 17 countries, including Italy, Greece, Netherlands, Germany, Czechia. These are trial locations, not confirmed office locations or countries where Emn Trial Office S.r.l. Impresa Sociale delivered services.
What can this page tell me about Emn Trial Office S.r.l. Impresa Sociale's trial experience?
Browse 9 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Emn Trial Office S.r.l. Impresa Sociale. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Emn Trial Office S.r.l. Impresa Sociale